

PRODUCT INFORMATION

Common Name	SGN-70, h1F6
Conjugate	Unconjugated
Synonyms	CD70;CD27L;CD27LG;TNFSF7
Applications	ELISA; Flow Cyt
Recommended Dilutions	ELISA 1:5000-10000; Flow Cyt 1:100
Formulation & Reconstitution	Lyophilized from sterile PBS, pH 7.4. Normally 5% - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution.
Host Species	Homo sapiens
IgG type	Human IgG1 - kappa
Reactivity	Human
Target	CD70
Uniprot ID	P32970
Description	Anti-CD70 (vorsetuzumab biosimilar) mAb
Delivery	In Stock
Storage&Shipping	Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.
Background	Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals.
Usage	Research use only



Anti-CD70 (vorsetuzumab biosimilar) mAb ELISA

0.2µg of Human CD70, mFc-His Tagged protein per well




Figure 1 . ELISA plate pre-coated by 2 µg/ml (100 µl/well) Human CD70, mFc-His tagged protein PME100042 can bind Anti-CD70 Neutralizing antibody in a linear range of 3.91-139.9 ng/ml.




Figure 2. HEK293 cell line transfected with irrelevant protein (B) and human CD70 (A) were surface stained with anti-CD70 neutralizing antibody 1µg/ml (vorsetuzumab) followed by Alexa 488-conjugated anti-human IgG secondary antibody.






Figure 3. Flow cytometry analysis of antigen binding of anti-human CD70 mAb(BME100005).
(A) A clear peak shift of BME100005 was seen compared to the control when incubated with CD70-expressing THP1 cells, indicating strong binding of BME100005 to CD70. Antibodies were incubated at 2 μ g/mL.

